Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study

Study limitation reported by the research below: “Brand tag 'Imfinzi' applies to durvalumab; tremelimumab's brand name (Imjudo) was not mentioned in the source text and was therefore omitted.”